Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

T-cell therapy at the threshold

Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Carl June, Steven A Rosenberg, Michel Sadelain or Jeffrey S Weber.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

June, C., Rosenberg, S., Sadelain, M. et al. T-cell therapy at the threshold. Nat Biotechnol 30, 611–614 (2012). https://doi.org/10.1038/nbt.2305

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2305

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer